Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Hepatology (Baltimore, Md.)
|
March 30, 2007
Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding
Thomas F Imperiale, Robert W Klein, Naga Chalasani
The American Journal of Gastroenterology
|
December 23, 2003
Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis
Thomas F Imperiale, Naga Chalasani, Robert W Klein
Biomaterials
|
November 12, 2003
The strength of acrylic bone cement cured under thumb pressure
Robert W Klein, Christopher P Scott, Paul A Higham
International Journal of Retina and Vitreous
|
November 17, 2016
Multimodal imaging of bilateral diffuse uveal melanocytic proliferation associated with an iris mass lesion
Jonathan Naysan, Claudine E Pang, Robert W Klein, et al.
Applied Health Economics and Health Policy
|
November 12, 2013
Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review
Ronald C Wielage, Julie A Myers, Robert W Klein, et al.
BMC Musculoskeletal Disorders
|
November 1, 2012
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Daniel R Murphy, Lee J Smolen, Timothy M Klein, et al.
Journal of Managed Care Pharmacy : JMCP
|
September 17, 2004
Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia
Robert L Ohsfeldt, Karl J Kreder, Robert W Klein, et al.
Applied Health Economics and Health Policy
|
April 26, 2013
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective
Ronald C Wielage, Megha Bansal, J Scott Andrews, et al.
Applied Health Economics and Health Policy
|
August 3, 2013
Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective"
Ronald C Wielage, Megha Bansal, J Scott Andrews, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 27, 2009
Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States
Leonard R Krilov, Debra L Palazzi, Ancilla W Fernandes, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Hepatology (Baltimore, Md.)
|
March 30, 2007
Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding
Thomas F Imperiale, Robert W Klein, Naga Chalasani
The American Journal of Gastroenterology
|
December 23, 2003
Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis
Thomas F Imperiale, Naga Chalasani, Robert W Klein
Biomaterials
|
November 12, 2003
The strength of acrylic bone cement cured under thumb pressure
Robert W Klein, Christopher P Scott, Paul A Higham
International Journal of Retina and Vitreous
|
November 17, 2016
Multimodal imaging of bilateral diffuse uveal melanocytic proliferation associated with an iris mass lesion
Jonathan Naysan, Claudine E Pang, Robert W Klein, et al.
Applied Health Economics and Health Policy
|
November 12, 2013
Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review
Ronald C Wielage, Julie A Myers, Robert W Klein, et al.
BMC Musculoskeletal Disorders
|
November 1, 2012
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Daniel R Murphy, Lee J Smolen, Timothy M Klein, et al.
Journal of Managed Care Pharmacy : JMCP
|
September 17, 2004
Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia
Robert L Ohsfeldt, Karl J Kreder, Robert W Klein, et al.
Applied Health Economics and Health Policy
|
April 26, 2013
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective
Ronald C Wielage, Megha Bansal, J Scott Andrews, et al.
Applied Health Economics and Health Policy
|
August 3, 2013
Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective"
Ronald C Wielage, Megha Bansal, J Scott Andrews, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 27, 2009
Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States
Leonard R Krilov, Debra L Palazzi, Ancilla W Fernandes, et al.
Page
of 3